Updated Guidelines for Treating Type 2

By Tara Dairman | October 24, 2008 5:01 pm

This week, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) updated their recommendations for how Type 2 diabetes should be treated. The new guidelines have been published online in the journals Diabetes Care and Diabetologia and will be published in print in the January 2009 issue of Diabetes Care.

Treatment recommendations were originally published in 2006 to guide health-care providers on how to bring down high blood glucose levels in people with Type 2 diabetes. According to a statement released this week by the ADA and EASD, the latest revisions “tak[e] into account new medications that have come on the market and the most current scientific data regarding previously recommended drugs.”


The revised treatment protocol looks like this:

The new guidelines recommend that people newly diagnosed with Type 2 diabetes see their doctors every three months, as did the old guidelines. The goal is to allow timely assessments and treatment adjustments so that people can rapidly achieve and maintain near-normal blood glucose and HbA1c[7] levels.

The major differences in this revision of treatment guidelines are the following:

Rosiglitazone has been in the news frequently over the last year because of associations with heart attack[8], congestive heart failure[9], and bone fractures[10]. The latter two side effects have also been associated with pioglitazone, though pioglitazone does not appear to increase risk of heart attack.

You can download a PDF of the Diabetes Care article outlining the revised guidelines and the research behind them here[11].

  1. metformin: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Metformin
  2. insulin: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Insulin
  3. sulfonylurea: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Sulfonylureas
  4. thiazolidinedione: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Thiazolidinediones
  5. exenatide: http://www.diabetesselfmanagement.com/articles/Insulin/Exenatide_and_Pramlintide
  6. hypoglycemia: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Hypoglycemia
  7. HbA1c: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/HbA1c
  8. heart attack: http://www.diabetesselfmanagement.com/blog/Tara_Dairman/Type_2_Drug_Avandia_Linked_to_Increased_Risk_of_Heart_Attacks
  9. congestive heart failure: http://www.diabetesselfmanagement.com/articles/Diabetes_Definitions/Congestive_Heart_Failure_CHF
  10. bone fractures: http://www.diabetesselfmanagement.com/blog/Tara_Dairman/Diabetes_Drug_Linked_to_Fracture_Risk
  11. here: http://care.diabetesjournals.org/cgi/content/abstract/dc08-9025v1

Source URL: https://www.diabetesselfmanagement.com/blog/updated-guidelines-for-treating-type-2/

Tara Dairman: Tara Dairman is a former Web Editor of DiabetesSelfManagement.com. (Tara Dairman is not a medical professional.)

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.